GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

and should remove the majority of Zantac overhang on the stock,” the analysts said. GSK has struck the agreement without ...

(Bloomberg) -- GSK Plc is facing a whistleblower lawsuit that could potentially cost it billions of dollars from the laboratory that revealed the presence of a probable carcinogen in Zantac ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

GSK earlier this month agreed to pay $2.3 billion to end lawsuits alleging that Zantac caused cancer, despite the group not admitting liability. Stripping out the litigation costs, GSK said ...

Additionally, GSK has reached an agreement in principle to pay a total of $70 million to settle a Zantac qui tam complaint ... reductions in future legal costs. The costs of these settlements ...

There had been speculation initially that GSK and other companies involved in the sale of ranitidine-based products could face billions of dollars in settlement costs. Since then, however ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer.